Matches in SemOpenAlex for { <https://semopenalex.org/work/W1965877100> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W1965877100 endingPage "231" @default.
- W1965877100 startingPage "223" @default.
- W1965877100 abstract "In this study, the authors assessed the endocrine system and glucose tolerance in obese and non-obese women chronically treated with typical antipsychotic drugs (AP). In particular, we tested the hypotheses that these subjects display hypogonadism and increased insulin resistance compared to healthy weight-matched controls, as these abnormalities create a tendency towards excessive body weight gain. Twenty-six AP-treated women were matched with 26 healthy women by age, body mass index and day of the menstrual cycle. The following serum variables were evaluated in each subject: glucose tolerance after an oral glucose overload, insulin, leptin, β-endorphin, reproductive hormones, adrenal steroids and lipids. Compared to controls, AP-treated women displayed significantly higher levels of basal glucose, insulin after 60 min of the glucose overload, prolactin, thyroid stimulating hormone and β-endorphin, with lower levels of C-Peptide, progesterone, 17-OH progesterone, androstenedione and high-density lipoprotein cholesterol. The levels of estradiol, estrone and leptin did not differ between the groups. Thus, women treated with typical AP appeared to display more insulin resistance than healthy controls, predisposing them to excessive weight gain. Insulin sensitivity might be further impaired when the subject switches to atypical AP administration. Metformin and related agents may reduce body weight in these subjects. The high levels of the opiate β-endorphin suggest that opiate antagonists such as naloxone and naltrexone might be useful as well. Even though the luteal phase of the menstrual cycle appears to be severely disturbed, the normal serum levels of estradiol and estrone do not support the proposal derived from animal experimental studies about the use of estrogens or tamoxifen to counteract AP-induced obesity." @default.
- W1965877100 created "2016-06-24" @default.
- W1965877100 creator A5027167344 @default.
- W1965877100 creator A5035740812 @default.
- W1965877100 creator A5041927043 @default.
- W1965877100 creator A5045095914 @default.
- W1965877100 creator A5051656938 @default.
- W1965877100 creator A5053374054 @default.
- W1965877100 creator A5088198069 @default.
- W1965877100 date "2001-10-26" @default.
- W1965877100 modified "2023-10-14" @default.
- W1965877100 title "Endocrine and Metabolic Abnormalities Involved in Obesity [nl]Associated with Typical Antipsychotic Drug Administration" @default.
- W1965877100 doi "https://doi.org/10.1055/s-2001-18034" @default.
- W1965877100 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11778142" @default.
- W1965877100 hasPublicationYear "2001" @default.
- W1965877100 type Work @default.
- W1965877100 sameAs 1965877100 @default.
- W1965877100 citedByCount "51" @default.
- W1965877100 countsByYear W19658771002012 @default.
- W1965877100 countsByYear W19658771002013 @default.
- W1965877100 countsByYear W19658771002014 @default.
- W1965877100 countsByYear W19658771002019 @default.
- W1965877100 countsByYear W19658771002023 @default.
- W1965877100 crossrefType "journal-article" @default.
- W1965877100 hasAuthorship W1965877100A5027167344 @default.
- W1965877100 hasAuthorship W1965877100A5035740812 @default.
- W1965877100 hasAuthorship W1965877100A5041927043 @default.
- W1965877100 hasAuthorship W1965877100A5045095914 @default.
- W1965877100 hasAuthorship W1965877100A5051656938 @default.
- W1965877100 hasAuthorship W1965877100A5053374054 @default.
- W1965877100 hasAuthorship W1965877100A5088198069 @default.
- W1965877100 hasConcept C126322002 @default.
- W1965877100 hasConcept C134018914 @default.
- W1965877100 hasConcept C2777164284 @default.
- W1965877100 hasConcept C2777391703 @default.
- W1965877100 hasConcept C2778656385 @default.
- W1965877100 hasConcept C2779058012 @default.
- W1965877100 hasConcept C2779064019 @default.
- W1965877100 hasConcept C2779306644 @default.
- W1965877100 hasConcept C2780613262 @default.
- W1965877100 hasConcept C511355011 @default.
- W1965877100 hasConcept C71315377 @default.
- W1965877100 hasConcept C71924100 @default.
- W1965877100 hasConceptScore W1965877100C126322002 @default.
- W1965877100 hasConceptScore W1965877100C134018914 @default.
- W1965877100 hasConceptScore W1965877100C2777164284 @default.
- W1965877100 hasConceptScore W1965877100C2777391703 @default.
- W1965877100 hasConceptScore W1965877100C2778656385 @default.
- W1965877100 hasConceptScore W1965877100C2779058012 @default.
- W1965877100 hasConceptScore W1965877100C2779064019 @default.
- W1965877100 hasConceptScore W1965877100C2779306644 @default.
- W1965877100 hasConceptScore W1965877100C2780613262 @default.
- W1965877100 hasConceptScore W1965877100C511355011 @default.
- W1965877100 hasConceptScore W1965877100C71315377 @default.
- W1965877100 hasConceptScore W1965877100C71924100 @default.
- W1965877100 hasIssue "06" @default.
- W1965877100 hasLocation W19658771001 @default.
- W1965877100 hasLocation W19658771002 @default.
- W1965877100 hasOpenAccess W1965877100 @default.
- W1965877100 hasPrimaryLocation W19658771001 @default.
- W1965877100 hasRelatedWork W1494203808 @default.
- W1965877100 hasRelatedWork W2013849732 @default.
- W1965877100 hasRelatedWork W2040440140 @default.
- W1965877100 hasRelatedWork W204340081 @default.
- W1965877100 hasRelatedWork W2189117092 @default.
- W1965877100 hasRelatedWork W2361602205 @default.
- W1965877100 hasRelatedWork W2409870954 @default.
- W1965877100 hasRelatedWork W2410344513 @default.
- W1965877100 hasRelatedWork W3155385925 @default.
- W1965877100 hasRelatedWork W2207069910 @default.
- W1965877100 hasVolume "34" @default.
- W1965877100 isParatext "false" @default.
- W1965877100 isRetracted "false" @default.
- W1965877100 magId "1965877100" @default.
- W1965877100 workType "article" @default.